Johannes Vermehren (J Vermehren)

Publication Activity (10 Years)

Years Active: 2017-2019
Publications (10 Years): 8

Top Topics

Ultrasound Guided

Circulating Tumor

Hepatitis C Virus

Top Venues

Alimentary pharmacology & therapeutics

Journal of gastroenterology and hepatology

This page only lists publications with an associated author ORCID identifier.

Publications

Marcus Maximilian Mücke, Victoria Therese Mücke, Johannes Vermehren
Letter: adoption of uniform nomenclature is crucial for estimating the true risk of HBV reactivation in patients treated with direct-acting antivirals for hepatitis C. Alimentary pharmacology & therapeutics 47 (11) (2019)
Johann von Felden, Johannes Vermehren, J Schulze Zur Wiesch, C Sarrazin, S Christensen
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply. Alimentary pharmacology & therapeutics 47 (11) (2019)
L Kuhnhenn, B Jiang, A Kubesch, Johannes Vermehren, Viola Knop, S Susser, J Dietz, G Carra, Fabian Finkelmeier, G Grammatikos, S Zeuzem, C Sarrazin, E Hildt, Kai-Hendrik Peiffer
Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection. Alimentary pharmacology & therapeutics 47 (11) (2018)
Johann von Felden, Johannes Vermehren, P Ingiliz, S Mauss, T Lutz, K G Simon, H W Busch, A Baumgarten, K Schewe, D Hueppe, C Boesecke, J K Rockstroh, M Daeumer, N Luebke, J Timm, J Schulze Zur Wiesch, C Sarrazin, S Christensen
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Alimentary pharmacology & therapeutics 47 (9) (2018)
Jan Peveling-Oberhag, Imad Osman, Dirk Walter, Natalie Filmann, Katharina Stratmann, Johannes Hausmann, Viola Knop, Oliver Waidmann, Johannes Vermehren, Eva Herrmann, Stefan Zeuzem, Mireen Friedrich-Rust, Irina Blumenstein, Jörg G Albert
Risk factors for early and late procedure-related adverse events in percutaneous endoscopic gastrostomy: A single center, retrospective study. Journal of gastroenterology and hepatology 34 (2) (2018)
M M Mücke, V T Mücke, Johannes Vermehren
Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals - Authors' reply. Alimentary pharmacology & therapeutics 46 (9) (2017)
V T Mücke, M M Mücke, Kai-Hendrik Peiffer, N Weiler, T M Welzel, C Sarrazin, S Zeuzem, A Berger, Johannes Vermehren
No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Alimentary pharmacology & therapeutics 46 (4) (2017)
M M Mücke, V T Mücke, Johannes Vermehren
Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy - authors' reply. Alimentary pharmacology & therapeutics 46 (7) (2017)